Are you offering chemotherapy for premenopausal patients with HR+ node-positive breast CA with OncoType dx scores in the intermediate range of 11-25?

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

How do you reconcile the apparent benefit in all patients in this group as opposed to the differential effects in premenopausal HR+ node-negative patients with intermediate risk in TAILORx?

Answer from: Medical Oncologist at Academic Institution

This is a great question. Yes, I typically recommend adjuvant chemotherapy in premenopausal women with early stage HR+ breast cancer with nodal involvement regardless of Oncotype DX RS. I do not send an Oncotype DX score in this setting due to the modest benefit of chemotherapy seen in premenopausal...

Comments

Medical Oncologist at University of Rochester Medical Center
Hi, Dr. @Bhave! What about in the case of micromet...

Medical Oncologist at NYU Winthrop Hospital
For micrometastases, I recommend chemotherapy in p...

Medical Oncologist at Warren Alpert Medical School of Brown University
I disagree with this as a blanket recommendation. ...

Answer from: Medical Oncologist at Community Practice

The RxPONDER trial was conducted to definitively answer the question of whether Recurrence Score (RS) could be used to predict which women with HR+, HER-, node-positive breast cancer would benefit from chemotherapy. 5,083 women with this cancer and with an RS of 25 or less, were randomly assigned to...

Answer from: Medical Oncologist at Community Practice

What is the estimated benefit of chemotherapy in genomic low-risk RS for premenopausal patients? Would you consider or offer ovarian suppression as an alternative to chemotherapy, since possibly the most benefit of chemo for this patient population might be derived from ovarian suppression as a side...

Related Questions